UroGen Pharma(US:URGN) Prnewswireยท2025-06-10 09:45Core Viewpoint - A class action securities lawsuit has been filed against UroGen Pharma Ltd. due to alleged securities fraud affecting investors between July 27, 2023, and May 15, 2025 [1][2]. Group 1: Lawsuit Details - The complaint alleges that UroGen Pharma Ltd. made false statements regarding the ENVISION clinical study, claiming it was not designed to provide substantial evidence of effectiveness for UGN-102 due to the absence of a concurrent control arm [2]. - It is claimed that UroGen Pharma Ltd. would struggle to demonstrate that the duration of response endpoint was attributable to UGN-102, and that the company ignored FDA warnings about the study design [2]. - The lawsuit suggests that there was a significant risk that the New Drug Application (NDA) for UGN-102 would not be approved, leading to misleading positive statements about the company's business and prospects [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until July 28, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].